Fleshner Neil E.

Chief Medical Officer, DirectorPOINT Biopharma Global Inc. (PNT) · full profile →Form 4 · filed Dec 27, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 22, 2023Tender(U)2.8M0
Dec 22, 2023Tender(U)3580
Dec 22, 2023Tender(U)233K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 27, 2023Disposed to issuer(D)84K0
Dec 27, 2023Disposed to issuer(D)60K0
Dec 27, 2023Disposed to issuer(D)25K0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-129772) within minutes of acceptance. Every field above traces to the original document. Verify it directly: